ADC Therapeutics Financials - Benzinga

ADC Therapeutics SA

ADCTNYSE

Trade with Public

Trade with Public

$1.01

-0.04-3.81%

At close: Aug 14, 5:00 PM EST

$1.00

-0.01-0.99%

After Hours: 6:35 PM EST

PRO

Why Is It Moving?™:ADC Therapeutics shares are trading lower after the company reported mixed ...

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 1 day ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

ADC Therapeutics Financials

ADC Therapeutics (ADCT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 56 percent increase over losses of $(0.25) per share from the

Benzinga Newsdesk

PRO
ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 4, 2026

Benzinga Insights

ADC Therapeutics: Q4 Earnings Insights

Benzinga Insights

PRO
ADC Therapeutics Q4 Adj. EPS $(0.09) Beats $(0.27) Estimate, Sales $23.058M Beat $21.390M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.27) by 66.42 percent. This is a 64 percent increase over losses of $(0.25) per share from the

Benzinga Newsdesk

Earnings Scheduled For March 10, 2026

Benzinga Insights